Latin America: Towards Medicine Sovereignty
When it comes to pharmaceutical exports, Latin America has historically been confined to the margins of the global life science industry. In 2023, the region accounted for a mere one…
Address: Av. Morumbi, 8264 – Brooklin CEP 04703-002 – São Paulo, SP,Brazil
Tel: (11) 2144-6911
Eli Lilly and Company, Lilly or simply, as it is known that the pharmaceutical industry of North America, has 134 years of existence. The company, with global operations and one of the largest funds applied research and development, is today one of the largest biotech companies in the world and owns brands that have become synonymous with ancient relief for diseases such as Prozac and Zyprexa Cialis, and prefers to characterized as a company that sells innovation in physical and mental health through medications that are usually the pioneers and most advanced in their therapeutic classes.
In Brazil, the company participates in the construction of the pharmaceutical market 66 years ago, and is one of the most important industries in the country, one of the leaders in the areas of mental health, oncology and women’s health.
Humulin, Humatrope, Humalog, Prozac, Gemzar , ReoPro, of Zyprexa, Evista, Xigris, of Cialis, Fort, Cymbalta and Byetta
When it comes to pharmaceutical exports, Latin America has historically been confined to the margins of the global life science industry. In 2023, the region accounted for a mere one…
Dirk van Niekerk, President and CEO of Boehringer Ingelheim South America, identifies Latin America as a pivotal growth engine. Focusing on cardio, renal, metabolic and oncology pillars, the firm is…
Fernando Almeida, EVP China & International Markets, discusses his global pharma career and Chiesi’s evolution into a high-performing, innovation-led group. He highlights strong double-digit growth, disciplined investment, and expansion across…
From cancer treatments to cardiovascular drugs, access to innovative medicines in South America lags behind developed market norms with patients forced to endure considerable delays for therapies that are already…
Latin America faces one of the most complex healthcare landscapes in the world, where fast-growing demand collides with deep structural inequities and limited resources. In this interview, Fabrizio Signorin, President…
Marco Billi, International CEO of Eurofarma, shares his perspective on the company’s evolution from a Brazilian CMO (Contract Manufacturing Organisation) into one of Latin America’s most internationally active pharmaceutical groups.…
Latin America’s largest and most dynamic pharma market is booming. Despite sluggish macroeconomic growth, agile local firms are consolidating their positions to serve Brazilian patients, while a spate of technology…
Danielle Bibas leads Pierre Fabre’s operations in Brazil, overseeing three key dermo-cosmetic brands – Avène, Darrow, and Ducray – in the world’s third-largest beauty market. Since assuming the role in…
Rare diseases have long fallen through the cracks of Latin America’s health systems, but few figures have done more to change that reality than Toni Daher. What started as a…
Brazil’s push to modernise its health system has put Interfarma at the centre of the region’s biggest access debate. Since taking over the presidency in 2023, Renato Porto has steered…
Alexandre Gibim, senior Vice President of Latin America at AstraZeneca, brings extensive global pharmaceutical leadership experience spanning China, the US, and Canada. In this exclusive interview, he articulates AstraZeneca’s strategic…
Haig Yeghiaian, General Manager at LEO Pharma Brazil, brings extensive therapeutic area expertise spanning HIV, nephrology, and dermatology to his leadership of the company’s multifaceted Brazilian operations. Under his stewardship,…
See our Cookie Privacy Policy Here
